available for iOS, Android & web
August 14, 2012
Buoyed by strong revenue growth and significantly lighter restructuring charges, Parexel International reported operating income of $25.5 million for the final quarter of its 2012 fiscal year, more than 16 times the income of US$1.6 million recorded in the fourth quarter of FY 2011.
July 26, 2012
Restructuring charges and other non-recurring items amounting to US$5.6 million cut into ICON’s profits for the second quarter of fiscal 2012, dragging operating income for the three months ended 30 June down by 29% year on year.
May 01, 2012
After tightening up its financial guidance at the second-quarter stage, Parexel was on a more bullish track in the three months ended 31 March 2012, raising its revenue forecast for the fiscal year and outpacing analysts’ expectations as operating income jumped 29% despite continuing restructuring charges.
International Clinical Researcher of the Year 2016
Last chance to enter!
PharmaTimes 2015 Copyright | RSS Feed Subscriptions